Who is the CEO of Goldline Pharmaceutical Ltd?
- Answer Field
-
Amol Laxmikant Mujumdar is the Promoter and Managing Director of Goldline Pharmaceutical Ltd.
Goldline Pharmaceuticals is engaged in the marketing and distribution of pharmaceutical products across multiple therapeutic categories under the “Goldline” brand. The Goldline Pharmaceutical IPO is scheduled to open on May 12, 2026, and close on May 14, 2026. The issue consists of 27,00,000 shares with a price band of ₹41 to ₹43 per share and is proposed to be listed on the BSE SME platform. The company plans to utilise the IPO proceeds towards repayment of certain borrowings and general corporate purposes.
Goldline Pharmaceuticals is engaged in the marketing and distribution of pharmaceutical products across multiple therapeutic categories under the “Goldline” brand. The company’s product portfolio caters to healthcare segments including cardiology, diabetology, orthopaedics, paediatrics, gastroenterology, neurology, critical care, and supportive care. Instead of manufacturing medicines directly, the company follows a third-party manufacturing model where products are produced by external manufacturing partners based on its specifications and market requirements. Its operations are supported by a distributor-led supply network serving retailers, wholesalers, hospitals, and healthcare providers across selected Indian states. The company’s business approach remains focused on product branding, distribution management, and therapeutic expansion in domestic markets.
Investors planning to apply for the Goldline Pharmaceutical IPO can do so through the ASBA facility available via net banking platforms or through supported trading and demat applications. Applicants are generally required to log in to their trading or banking platform, select the IPO section, choose the Goldline Pharmaceutical IPO, enter the bid quantity and price within the specified range, and submit the application using their UPI ID or ASBA authorisation process. Before applying, investors may review the company’s prospectus, financial information, risk factors, business operations, and issue-related details available in the official filing documents. IPO allotment status can usually be checked through the registrar’s website after the basis of allotment is finalised.
For more details, visit the Goldline Pharmaceutical IPO page.
Details | Information |
IPO Date | May 12, 2026 to May 14, 2026 |
Issue Size | 27,00,000 shares (agg. up to ₹11.61 Cr) |
Price Band | ₹41 to ₹43 per share |
Lot Size | 3,000 shares |
Listing At | BSE, SME |
Market Maker | Nirman Share Brokers Pvt. Ltd. |
Prepayment or repayment of all or a portion of certain outstanding borrowings availed by the company
General corporate purposes
Event | Date |
IPO Open Date | Tue, May 12, 2026 |
IPO Close Date | Thu, May 14, 2026 |
Tentative Allotment | Fri, May 15, 2026 |
Initiation of Refunds | Mon, May 18, 2026 |
Credit of Shares to Demat | Mon, May 18, 2026 |
Tentative Listing Date | Tue, May 19, 2026 |
Cut-off time for UPI mandate confirmation | 5 PM on Thu, May 14, 2026 |
₹41 to ₹43 per share
Application | Lots | Shares | Amount |
Individual investors (Retail) (Min) | 2 | 6,000 | ₹2,58,000 |
Individual investors (Retail) (Max) | 2 | 6,000 | ₹2,58,000 |
S-HNI (Min) | 3 | 9,000 | ₹3,87,000 |
S-HNI (Max) | 7 | 21,000 | ₹9,03,000 |
B-HNI (Min) | 8 | 24,000 | ₹10,32,000 |
The Goldline Pharmaceutical IPO application process can be completed online through your trading platform. Below is a step-by-step guide to applying for the IPO:
Step 1: Login to Your Trading Platform
Access your trading account using the trading platform.
Step 2: Navigate to the IPO Section
Go to the IPO section to view active IPO listings.
Step 3: Select the Open IPO and Click Apply
Locate Goldline Pharmaceutical IPO in the list of available IPOs and click the ‘Apply’ button.
Step 4: Enter the Quantity of Shares You Wish to Apply For
Specify the number of shares (lot size: 3,000 shares) within the price band of ₹41 to ₹43 per share.
Step 5: Provide Your UPI ID
Enter your UPI ID for payment authorisation and ensure sufficient funds in your bank account.
Step 6: Confirm the Application
Review your application details and confirm the UPI mandate before 5 PM on the last application day.
Step 7: Complete the Process and Wait for IPO Allotment Status
Submit the application and monitor the allotment status to check if shares have been allocated to you.
The allocation of shares in the Goldline Pharmaceutical IPO is structured across investor categories in line with applicable regulatory requirements. The issue provides defined reservations for qualified institutional buyers, non-institutional investors, and retail individual investors, with each category allotted a specified proportion of the net issue. This allocation framework outlines how the total issue is distributed among different classes of investors.
Investor Category | Shares Offered | % of Net Issue | % of Total Issue |
QIB Shares Offered | 12,72,000 | 49.65% | 47.11% |
− Anchor Investor Shares Offered | 7,32,000 | - | 27.11% |
− QIB (Ex. Anchor) Shares Offered | 5,40,000 | - | 20.00% |
NII (HNI) Shares Offered | 3,90,000 | 15.22% | 14.44% |
Retail Shares Offered | 9,00,000 | 35.13% | 33.33% |
Firm Reservations | |||
Market Maker Shares Offered | 1,38,000 | - | 5.11% |
Total Shares Offered | 27,00,000 | 100.00% | 100.00% |
This reservation structure reflects the categorisation and allocation approach disclosed for the issue, indicating the proportion of shares available to each investor segment.
Total Assets: Grew from ₹19.39 crore in FY23 to ₹26.28 crore as of March 2025.
Total Income: Recorded at ₹28.06 crore in March 2025, as compared to ₹19.85 crore in FY23.
Profit After Tax (PAT): Reported at ₹2.83 crore in March 2025, and ₹0.26 crore in FY23.
Net Worth: Recorded at ₹10.35 crore in March 2025, compared to ₹5.89 crore in FY23.
Reserves & Surplus: Recorded at ₹1.65 crore in March 2025, compared to ₹2.08 crore in FY23.
Total Borrowings: Stood at ₹11.03 crore in March 2025, as compared to ₹10.83 crore in FY23.
EBITDA: Stood at ₹5.83 crore in March 2025 in comparison to ₹2.19 crore in FY23.
The company reported growth in its overall asset base during the reviewed financial period, reflecting expansion in business operations and working capital requirements.
Revenue generation showed an upward trend over the last few financial years, supported by expansion in product distribution, therapeutic coverage, and geographical presence across selected states.
Profitability improved during the period under review, indicating changes in operational performance and business scale.
Net worth increased over the reviewed period, supported by business earnings and operational growth.
Operating performance reflected movement during the financial period, supported by growth in income and business activities across pharmaceutical product categories.
Borrowings remained broadly stable during the period, indicating continued utilisation of debt for operational and business requirements.
The company’s business model continues to focus on pharmaceutical branding, third-party manufacturing partnerships, distributor-led supply, and expansion across multiple healthcare segments.
Going forward, growth prospects may remain linked to product portfolio expansion, distributor network strengthening, healthcare demand trends, regulatory compliance requirements, and market penetration across domestic regions.
The company follows a third-party manufacturing model and depends on external manufacturing partners for product production. Any disruption related to manufacturing arrangements, quality standards, regulatory approvals, or supply timelines may affect business operations and product availability.
The pharmaceutical sector remains subject to regulatory compliance requirements, pricing controls, and changes in healthcare policies. In addition, the company’s operations are concentrated across selected domestic regions, which may expose the business to regional market conditions, distributor-related dependencies, and competitive pressures within the pharmaceutical industry.
The company operates across multiple therapeutic categories including cardiology, diabetology, paediatrics, orthopaedics, neurology, gastroenterology, and critical care. Expansion of its product portfolio and continued demand for pharmaceutical products across healthcare segments may support business growth opportunities.
Growth prospects may remain linked to expansion in distributor networks, increasing presence across additional domestic markets, and rising healthcare awareness. The company’s focus on branding, distributor-led supply, and hospital procurement support may also contribute to operational expansion in the pharmaceutical distribution segment.
KPI | Dec 31, 2025 | Mar 31, 2025 |
ROE | 21.02% | 35.83% |
ROCE | 24.22% | 38.45% |
Debt/Equity | 1.07 | 1.50 |
RoNW | 17.99% | 27.37% |
PAT Margin | 10.38% | 10.09% |
EBITDA Margin | 19.41% | 20.78% |
Price to Book Value | 3.47 |
Registrar | Lead Manager(s) |
Bigshare Services Pvt. Ltd. | Cumulative Capital Pvt. Ltd. |
103, F-1, Leela Apartment, Shilpa HSG Society,
Near Saptagiri Nagar, Shanidham,
Narendra Nagar,
Nagpur, Maharashtra, 440015
Phone: +91 712 2786666
Email: info@goldlinepharma.in
Website: https://www.goldlinepharma.in/
Interested in more opportunities? Check out our Upcoming IPO section for new listings and don’t forget to check your Goldline Pharmaceutical IPO allotment status.
Amol Laxmikant Mujumdar is the Promoter and Managing Director of Goldline Pharmaceutical Ltd.
The Goldline Pharmaceutical IPO is scheduled to open for subscription on May 12, 2026, and close on May 14, 2026. The IPO is proposed to be listed on the BSE SME platform.
Goldline Pharmaceuticals is engaged in the marketing and distribution of pharmaceutical products across multiple therapeutic categories under the “Goldline” brand. The company follows a third-party manufacturing model, where products are manufactured by external partners based on its specifications and distributed through its network across selected Indian states. The long-term sustainability of the business may remain linked to factors such as product portfolio expansion, distributor network management, regulatory compliance, healthcare demand trends, and relationships with manufacturing partners.
The Goldline Pharmaceutical IPO consists of 27,00,000 equity shares aggregating to ₹11.61 crore, depending on the final issue calculations and disclosures.
The ‘pre-apply’ facility allows investors to submit their IPO application details before the issue officially opens for subscription. The bid is generally processed once the IPO subscription window becomes active. Funds are usually blocked only after mandate approval through the applicable banking or UPI process during the IPO period.
The lot size for the Goldline Pharmaceutical IPO is 3,000 shares. For retail investors, the minimum application requires 2 lots, equivalent to 6,000 shares. Based on the upper price band, the minimum investment amount for retail applicants is approximately ₹2,58,000.
The tentative basis of allotment for the Goldline Pharmaceutical IPO is scheduled for May 15, 2026.
The registrar to the Goldline Pharmaceutical IPO is Bigshare Services Pvt. Ltd. The registrar generally handles allotment processing, refund-related activities, and IPO application status services.
There are no publicly stated governance issues or red flags highlighted. Investors may review the offer documents, including sections on management, board composition, and risk factors, for detailed and verified disclosures.
Investors can apply for the Goldline Pharmaceutical IPO through the ASBA facility available via supported banking platforms or through UPI-enabled trading applications. The process generally involves logging into the trading or banking platform, selecting the IPO section, choosing the Goldline Pharmaceutical IPO, entering the bid quantity and price within the specified range, submitting the UPI ID or ASBA mandate, and confirming the application before the cut-off time.
Yes, a Demat account is generally required to apply for the Goldline Pharmaceutical IPO because allotted shares are credited electronically to the investor’s Demat account before listing. Investors also typically require a trading account and a linked bank account for the IPO application process.
After the basis of allotment is finalised, investors can check the allotment status through the registrar’s website using details such as PAN number, application number, or Demat account information. If shares are allotted, they are usually credited to the investor’s Demat account before the listing date.
Disclaimer :
Investments in the securities market are subject to market risk, read all related documents carefully before investing. This content is for educational purposes only. Securities quoted are exemplary and not recommendatory.
The information on this website is provided on "AS IS" basis. Bajaj Broking (BFSL) does not warrant the accuracy of the information given herein, either expressly or impliedly, for any particular purpose and expressly disclaims any warranties of merchantability or suitability for any particular purpose. While BFSL strives to ensure accuracy, it does not guarantee the completeness, reliability, or timeliness of the information. Users are advised to independently verify details and stay updated with any changes. The securities are quoted as an example and not as a recommendation. Past performance is not necessarily a guide to future performance.
The information provided on this website is for general informational purposes only and is subject to change without prior notice. BFSL shall not be responsible for any consequences arising from reliance on the information provided herein and shall not be held responsible for all or any actions that may subsequently result in any loss, damage and or liability. Interest rates, fees, and charges etc., are revised from time to time, for the latest details please refer to our Pricing page.
Neither the information, nor any opinion contained in this website constitutes a solicitation or offer by BFSL or its affiliates to buy or sell any securities, futures, options or other financial instruments or provide any investment advice or service.
BFSL is acting as distributor for non-broking products/ services such as IPO, Mutual Fund, Insurance, PMS, and NPS. These are not Exchange Traded Products. For more details on risk factors, terms and conditions please read the sales brochure carefully before investing.
Content Partner - Dalal Street Investment Journal Wealth Advisory Private Limited
This article is for educational purposes only and should not be considered investment advice. Market investments are subject to risks. DSIJ Wealth Advisory Private Limited is a SEBI-registered Research Analyst (Reg. No: INH000006396) and Investment Adviser (Reg. No: INA000001142). Please consult your financial adviser before investing.
For more disclaimer, check here : https://www.bajajbroking.in/disclaimer
Level up your stock market experience: Download the Bajaj Broking App for effortless investing and trading